VivoSim Labs, Inc.
0R02.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.67M
Close$
Share Statistics
| Market cap | $3.67 Million |
|---|---|
| Enterprise Value | $2.32 Million |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | 525.92% |
|---|---|
| Return on Assets | -320.72% |
| Return on Invested Capital | -729.02% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 20.7 |
| Enterprise Value to EBIT | -0.16 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.14 |
| Debt to Equity | -0.13 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Organovo Holdings Inc
15 employees
CEO: Keith Murphy VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicolo...